Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast 2016-2027 -

Research and Markets
Posted on: 30 Oct 18

The "Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027" report has been added to's offering.

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NMOSD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Neuromyelitis Optica Spectrum Disorder market report gives the thorough understanding of the Neuromyelitis Optica Spectrum Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuromyelitis Optica Spectrum Disorder in the US, Europe, and Japan.

The Neuromyelitis Optica Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female] and NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

Key Topics Covered:

1. Key Insights

2. Neuromyelitis Optica Spectrum Disorder: Market Overview at a Glance

3. Neuromyelitis Optica Spectrum Disorder: Disease Background and Overview

4. Epidemiology and Patient Population

5. 7MM Total Prevalent Patient Population of NMO/NMOSD

6. Country Wise-Epidemiology of NMO/NMOSD

7. Market Drivers

8. Market Barriers

9. Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 30/10/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.